Dynavax Technologies | DVAX - Selling And Administration Expenses


Dynavax Technologies reported $40.09M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.



Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Adma Biologics USD 20.19M 2.86M Dec/2025
Agenus USD 10.56M 13.04M Dec/2025
Amgen USD 1.94B 237M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Glaxosmithkline GBP 3.56B 650.29M Dec/2025
Merck USD 2.85B 215M Dec/2025
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
TG Therapeutics USD 50.73M 12.64M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025